Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John H Barton

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Academic Medicine : Journal of the Association of American Medical Colleges|December 14, 2002
Patents, genomics, research, and diagnosticsJohn H Barton
Nature Biotechnology|August 11, 2006
Emerging patent issues in genomic diagnosticsJohn H Barton
Health Affairs (Project Hope)|May 27, 2004
TRIPS and the global pharmaceutical marketJohn H Barton
Bulletin of the World Health Organization|April 16, 2002
Research-tool patents: issues for health in the developing worldJohn H Barton
JAMA|October 27, 2005
The patents-based pharmaceutical development process: rationale, problems, and potential reformsJohn H Barton, Ezekiel J Emanuel
JAMA|December 29, 2005
Technology licensing: lessons from the US experienceGregory K Sobolski, John H Barton, Ezekiel J Emanuel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, Sharlene Litchy, John H Barton, et al.
The Oncologist|August 3, 2017
A Phase II Study with Lead-In Safety Cohort of 5-Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2-Positive Esophagogastric AdenocarcinomasGregg Shepard, Edward R Arrowsmith, Patrick Murphy, et al.
Cancer Investigation|March 10, 2010
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancerHoward A Burris, Suzanne F Jones, Dianna Shipley, et al.
Clinical Lung Cancer|November 5, 2003
Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trialJohn D Hainsworth, Joan B Erland, John H Barton, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Academic Medicine : Journal of the Association of American Medical Colleges|December 14, 2002
Patents, genomics, research, and diagnosticsJohn H Barton
Nature Biotechnology|August 11, 2006
Emerging patent issues in genomic diagnosticsJohn H Barton
Health Affairs (Project Hope)|May 27, 2004
TRIPS and the global pharmaceutical marketJohn H Barton
Bulletin of the World Health Organization|April 16, 2002
Research-tool patents: issues for health in the developing worldJohn H Barton
JAMA|October 27, 2005
The patents-based pharmaceutical development process: rationale, problems, and potential reformsJohn H Barton, Ezekiel J Emanuel
JAMA|December 29, 2005
Technology licensing: lessons from the US experienceGregory K Sobolski, John H Barton, Ezekiel J Emanuel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, Sharlene Litchy, John H Barton, et al.
The Oncologist|August 3, 2017
A Phase II Study with Lead-In Safety Cohort of 5-Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2-Positive Esophagogastric AdenocarcinomasGregg Shepard, Edward R Arrowsmith, Patrick Murphy, et al.
Cancer Investigation|March 10, 2010
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancerHoward A Burris, Suzanne F Jones, Dianna Shipley, et al.
Clinical Lung Cancer|November 5, 2003
Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trialJohn D Hainsworth, Joan B Erland, John H Barton, et al.
Pageof 2